תעתיק 🔗
0:02
Hello and welcome back to Existential Threads. This is my conversation with Dr. Matt Caroline Part two. So in part one, we did some serious debunking of the most popular diets. And now we're going to talk about the actual things beyond lifestyle that an individual can do today to maintain and optimize their health. Then we'll look at maybe the most promising molecule in aging today and why you might want to keep an eye on it. I think the lifestyle piece, you know, everybody can take steps to improve their lifestyle, even, you know, independent of socioeconomic status. Again, I recognize there are disparities in food quality. That is the truth. But you can still take steps to improve your quality of diet. Your exercise, your sleep, your social connections, all of that people can take action on. And that's important. But once you get outside of that, there are a few things that I think, you know, most people can do with that that are not, you know, hugely expensive. So, again, if you've got a primary care doc, I really think people should push push for, you know, at least the minimum of preventative diagnostics and blood testing. So, for example, you know, it's going to depend a little bit on your primary care situation. But, you know, most people don't get tested for vitamin deficiencies. And, you know, our data suggest that probably 80% of people, at least where I live in the Pacific Northwest. If you just look at the three that I think are particularly common, Vitamin D, B-12 and Omega three, probably 80% of people are deficient in one or more of those. That's a that's a big deal. And, you know, the impact on quality of life is pretty high. I mean, people will argue correlation versus causation. I think something that's important to recognize the difference. But unfortunately, sometimes people just argue it for the sake of argument. I don't think anybody can really make a good faith argument that being deficient in one or more of those things is a good thing. So why not fix it, right? Trivially easy to fix, maybe $100 to get the measured. So, you know, I think most people can do that. And if you're not getting that from your primary care doctor, first, ask for it. And if you still can't get it, there are now companies out there that offer direct to consumer blood tests. You can go get these things measured. So so those are the kinds of things I think that, you know, are low hanging fruit really don't take much effort to fix other than, you know, getting the right supplement and taking it and could have a relatively big impact for relatively low cost. You mentioned scans. I do think body composition, again, is something that that, you know, if if I were the health care czar, I would make sure everybody has access to this in the United States in their forties or fifties. I think knowing your body composition is really important. Your index is a good way to do it. It's relatively cheap. There are companies now that offer DEXA scans for, I don't know, 50 bucks, you know, So at least once a year, monitor your body composition and the things you look for are bone density. If you have low bone density or if your bone density is trending downward, you want to know that. So you can take steps to do something about it. Lean, mass, visceral, adipose. Those are all things that will come out of a DEXA scan that will tell you if you are on a path to, you know, frailty or metabolic disease, then you can take action and you can monitor. So those are the kinds I think about that aren't super expensive and that, you know, most people can afford and get access to. Okay. When it comes to this kind of advice, I always feel kind of conflicted because, you know, it's great that we have more tools and information and access and our standards are higher. We're more more proactive about our health. Some of us, we can ask our doctors for higher standards of care, but on the other hand, we're really, really way more preoccupied with our health. Which where do you draw the line between a healthy preoccupation with health and just health, anxiety and obsession? And I think maybe it depends on the person or maybe some of us don't really register the price that we pay, the mental and maybe also physical price that we pay for this preoccupation. So it's just something that I'm a bit conflicted about. So moving on, Matt mentioned DEXA scans, which I had known is bone density scans, but he says that there is much more to them than that. So DEXA was first developed, so DEXA stands for Dual X-ray or Absorptiometry, and it was first developed as a bone density assay. And so there are clinics you can go to who will give you a DEXA scan, but they will they will use the software in a way that only looks at bone density and usually looks at bone density. I think in the spine and in the hips, because that's where most fractures happen in the in the elderly. You can also go get a whole body DEXA in most of these clinics that will give you your your bone density and specific regions actually have the data for whole body. It comes off the machine. It's just the way they analyze the data and the whole body. DEXA will give you bone density in a bunch of different regions so you can get you'll get skull, spine, right leg, left leg, right arm, left arm, it'll give you body fat in each of those regions. And also obviously whole body percent body fat and it'll give you lean mass. Now, lean mass is an indirect calculation so that because of the way the X-ray scatter, you can get bone and fat and then you can figure out lean mass once you know what the bone and fat are. And there's an estimate for water, but it's pretty close. And the nice thing about DEXA is you can you can get the visceral, adipose and visceral adipose is this this fat tissue that seems to be probably most important for metabolic dysregulation. So insulin resistance and chronic inflammation for reasons I don't completely understand and I think are still being
Load full transcript
figured out, the visceral adipose seems to give off a lot more inflammatory signals. And so you get you get actually a measurement of visceral adipose and that's where you might have heard this term skinny fat. So there are people who have very low whole body body fat but actually have high, visceral, adipose. And so they are at higher risk of metabolic disease because they have these high, visceral, adipose depots. You will get that from a DEXA scan. Interestingly, those people also are usually low in lean mass. So that combination of having high visceral, adipose and low lean mass is like a double whammy for metabolic disease because your muscle mass is actually really good as an insulin sensitizing. And so if you get that combination, you're you're at very high risk of having metabolic disease. And so again, these are the kinds of things that will come out of a DEXA scan. And there are companies out there now the one that I know the most about, and I don't have any any equity in body spec, but I just know about them because I've used them, but I know the owners. So they are in, I think, five or six cities, Seattle is one of them. They have a mobile DEXA service that, you know, they have these sprinter vans that have a DEXA machine in them. They go to different fitness centers and so you can sign up, go for 50 bucks, get a Dexus can do that, you know, once every six months and it's like 15 minutes in and out. I was wondering if this level of nuance and diagnosis is helpful beyond telling us what we already know about steps we need to take to maintain and optimize our health like resistance training and a balanced diet. There are probably a lot of people out there in their thirties, forties, maybe even fifties who don't realize they're pre-diabetic or diabetic. In fact, I know there are a lot of people out there in that bucket, and oftentimes it's the kind of people that I was just talking about there. Lean right there, there don't have they don't have high body fat. They're usually under muscled, but they have high, visceral, adipose. And so, you know, this isn't the only. Show and blood tests. It it may or may not. So what you'll often see, because again, the standard primary care blood tests, what do they measure? They measure fasting glucose and a onesie, and that's it. And those are both I mean, they're okay, but they're relatively crude crude markers. So unless you do something like continuous glucose monitoring, you may not pick up a pre-diabetic or your doc would say, you know, like for you, right, you're pretty lean, you're pretty young, your doctor, you might have a fasting glucose in the I don't know, let's say 1.5 put you in the pre-diabetic range and you're able to see is like 5.7. Your doc would be like your fasting glucose is a little high. Let's just watch it right. Let's just see what happens. So you may not understand why that's happening unless you do a little bit more digging. We haven't talked about continuous glucose monitoring. That's the other tool. There's actually quite powerful for identifying prediabetes, diabetes, that's undiagnosed and also learning about how certain foods affect your metabolic homeostasis. But again, I think the other thing you get from Texas is the bone density. There are probably a lot of people out there who are on their way to osteoporosis or osteopenia and just don't know it. And if you if you recognize that in your thirties and forties, you can take steps to to make sure that when you get into your 50 or 6070s, you aren't going to be in that osteoporosis category. I was surprised to hear about all these options that Matt mentioned that are available to some of us, at least today in the medical world. But these are still very limited. And the truth is that we just don't have proper therapies yet when it comes to preventing age related diseases and a general decline that comes with age. So we need to ask ourselves what is the equivalent to antibiotics to vaccines when it comes to the diseases that come with aging and the decline that comes with aging. So many scientists like Matt have been working on therapies, and Matt specifically has dedicated the last two decades of his work to a molecule named rapamycin that is really promising when it comes to preventing, treating and maybe even reversing biological aging. Rapamycin is a drug that I've really been, you know, thinking about since about 2005. So so we you know, we were doing and what we call an unbiased genetic screen for genes that affected lifespan. This was when I was a post-doc and we came across mTOR just from that. So we weren't looking for it. It just came out of this genetic screen and as soon as we got into it, when we when we knocked it down, we knew we could increase lifespan. You know, I started looking to see what we knew about mTOR, and it turned out there was this drug rapamycin that was an inhibitor of entry. And since we were genetically knocking down enter, it made sense that the drug might have the same effect and it turned out that it did. And so, you know, me and a bunch of other people in the field have been interested in really trying to understand what are the mechanisms by which rapamycin has this effect. Is it universal? Does it work in every organism that we look at? You know what? How far can we push it? How how big are the effects? You know, what's the right dose, All of that stuff. How safe is it for the last 20 years or so? And I think we've learned we've learned a lot. We've learned that rapamycin seems to increase lifespan and importantly, delay pretty much every aspect of aging that that we look at. So functional declines, diseases of aging, tissue and organ health in every organism where this has been tested up through mice. Clearly in rodents, mice and rats, rapamycin has this anti-aging effect. You can start the treatment in middle age or later and still get most or all of the benefits, and you can do it pretty safely. So there's no real
evidence for significant side effects at the doses that seem to increase lifespan. So that largely comes from laboratory studies. And then in the you know, in the last ten years or so, there's been a growing interest in asking, you know, does this work outside of the laboratory? And so two places where I have been involved in doing some research is in pet dogs. So we have this dog aging project, part of which is a clinical trial to test whether rapamycin can increase lifespan and healthspan in companion dogs living with their owner. So in the human environment, we've done two short term safety trials. Both of them showed no significant side effects, and in both of them we found evidence for increased activity in the dogs getting rapamycin. They were double blind, placebo controlled. And in the first one we also found evidence for improved heart function and these are in middle aged dogs. So now we are kind of in the middle of the large clinical trial to really test whether rapamycin can in fact increase lifespan and healthspan in dogs, and that's called triad for test of rapamycin in aging dogs. And we don't know the answer yet because, because the dogs are still blinded. So so it'll be a little while before we actually know the answer to that. I thought it was super smart that Matt chose dogs to study aging because in this way he escaped two major challenges that we have with lab animals. First of all, diversity animals in the lab are not diverse. Genetically pet dogs are then environment labs. Animals in labs are obviously are not in an environment that has anything to do with human environment in our daily lives. Dogs, pet dogs definitely do. And then dogs also live considerably shorter lives than humans, which makes the study easier to actually complete. And also, of course, different. And then in humans, I think it's obviously a super interesting question whether rapamycin has effects on aging and health span. Again, we don't know with any certainty at this point. What I can say is there have been a couple of really well done double blind placebo controlled clinical trials with a derivative of rapamycin called everolimus that showed the ability of a six week treatment in healthy older people to improve immune function, immune function as as measured by response to a flu vaccine, and then risk of infection over the next. I don't remember whether six or nine months. So I think pretty good evidence, at least for immune function, that short term rapamycin treatment of people can have a positive effect and then there are I have no idea what the numbers are, but it's it's almost certainly more than 10,000 people taking rapamycin, what's called off label, meaning it's not for the FDA approved indication, but they got prescribed rapamycin by their physician. They're now taking it. And so we've been studying those people and trying to gather information from them. And we published a paper earlier, I guess it was last year in 2023, where we collected
data from 333 people who'd been using rapamycin off label. We compared it to about 150 people who'd never used rapamycin. And you know, again, that that type of data has intrinsic weaknesses. It's not the same quality as a placebo controlled clinical trial, but I think we learned some interesting things. One thing that seemed very apparent to me was when you look at the side effect risk, really the only thing that was significant, statistically significantly higher in the rapamycin treated group was mouth sores. And these were relatively mild now. So it's kind of like a canker sores that a lot of people get. Nothing else came out as being higher for side effects in the rapamycin group. Now that doesn't mean there weren't any, but nothing that was statistically significant. Interestingly, six other things came out as higher in the group that had never used rapamycin. Those might actually be benefits of rapamycin. That needs more study. But it was it was intriguing. I think that that that it was more side effects that were higher in the non users than in the users. The other thing that I think the signal was pretty robust for is that rapamycin seemed to confer some protection against severity of COVID 19 infection in long COVID. So the people who used rapamycin throughout a COVID 19 infection were statistically significantly less likely to have a moderate or severe case of COVID 19 or to go on and have symptoms consistent with long COVID. So so that's interesting. And that actually, I think, fits pretty well with the biology that we know about rapamycin, that it can have pretty potent anti-inflammatory effects, pretty potent immune modulating, immune strengthening effects, at least in certain contexts. So so I think there's reason to believe that rapamycin can have benefits at least for a subset of people. And so I think it's still a very interesting molecule to keep studying. I think there's lots of potential for rapamycin and potentially other mTOR inhibitors to be used to improve Healthspan in people, whether it'll increase lifespan on average and which people will benefit, which people won't. I think all of that still really remains to be determined. I have my own speculative ideas on that, but I don't really have a lot of data at this point to be able to to start to say with any certainty. When we hear about a drug for aging, many people think it's something like we're going to live forever, it's going to give us immortality. It's really scary and it's like we're not even close. That's not those are not the kinds of dilemmas we need to deal with these days. If we ever have something, it will probably be a combination of therapies. It's quite complex. It's a really complex problem aging. So it won't be like this one magic bullet and not likely just to drug. But we do know that my son has shown a real impact when it comes to a long list of animals that have been studied. So there is a good reason to believe that it will do something real for human beings, too. So now the question is, with so much funds that governments spend on health care for people suffering from AIDS related diseases, why is it still so hard to fund those trials to potentially approve those drugs, to make them available to the people? You know, it's an FDA approved drug. We know a ton about its safety profile. We know something about the dosing like we could do very, very well controlled clinical trials of rapamycin in people today for multiple age related endpoints. The barrier is resources, right? Nobody has stepped up to fund these trials. It is an obvious thing to do, trivial to implement, but you know, somebody's got to pay for it and there's no incentive for pharmaceutical companies to pay for those clinical trials because rapamycin is off patent. So it's low hanging fruit that apparently nobody wants to pick. Unfortunately. So there's this joke that the NIH, the National Institute on Aging, is actually that and I a National Institute on Alzheimer's, because that's where almost all of the funding goes. So I had to ask Matt, how did he do? Like who did he bribe to get an actual grant to study rapamycin and aging biology. So we went and got reviewed in a competitive process by other scientists. And I think the things that appealed to them were the fact that dogs are a very powerful model for understanding the biology of aging, and they have unique strengths over both laboratory animals and over humans in this regard. Now, obviously, you know, the NIH has mandated human health, so the project has to be relevant for human health in principle, for NIH to fund it. Now, I think we can we can have a debate about whether everything they find is actually relevant for human health. But it's supposed to be. So I think if you want to understand aging in humans, you can make an argument that we should study aging in humans, and that's great. The problem is, you know, we were just talking about a life span. You know, how would we know how much rapamycin can extend lifespan in humans? To do that experiment? You need about four decades, right? So or, you know, $2 billion. So it's just not feasible. It's not realistic to think about asking those kinds of questions in humans. Likewise, if you want to understand what are the most important genetic and environmental factors that influence the biology of aging in humans, you really have to do a 50 year longitudinal study of aging on, you know, 20,000 people. Again, that's going to cost hundreds of millions, if not billions of dollars to do, while not feasible to really do that. Well, there are some longitudinal studies of aging in people that have been quite informative, but they also, I think, have been lacking in a lot of the insights that we would like to have because it just cost too much. So dogs are a model that can address both of those things because they age, you know, roughly 7 to 10 times faster than people do. So you can do a large scale longitudinal study of aging
and you can do double blind placebo controlled clinical trials with lifespan as the endpoint in a few years, a few being 5 to 10. So I think that appealed to the reviewers that this was an animal that is genetically diverse, unlike most inbred strains of mice that shares the human environment. So you've kind of checked the two boxes that where mice are really lacking and that ages rapidly, and the fact that, you know, people love their dogs. Most dog owners consider their dog to be part of their family, right? So the impact of slowing aging, improving health spending, lifespan and people's family members, it's hard to argue that we're going to learn a lot about human biology and human aging. But even if we didn't, it's hard to argue that that's not going to have an impact on quality of life for people. So I think all of that, you know, contributed to the rationale for funding the dog aging project back in 2018, as well as I think the really solid scientific team that that that we put together at multiple institute institutions had, you know, really high quality biologists in the field of aging biology, high quality veterinarian is high quality data science people, high quality epidemiologists, geneticists, genome assists. So it was a really it was a really solid team. And so the reviewers felt that it was a project worth funding. After completing the five year funding from the NIH, Matt and his team have been able to fundraise to keep the project going for another year, but it's still unknown if the NIH is going to renew its support going forward. So in the meantime, the team has put together a nonprofit where philanthropic support can be received, and I would encourage you to consider making a donation. The website is Dog Aging Institute dot org. The mission of the Institute is not solely to fund the dog aging project. It's really to more broadly support research on aging and healthspan in dogs and potentially even in other companion animals, cats and other companion animals. But for the short term, the primary goal of raising funds for the Institute now is to support the dog aging project and keep it going. So is of course curious to know if this project could, when completed and successful, can help us accelerate studying and approving rapamycin for humans? You would hope so. I mean, again, I think it's really not clear to me why those trials haven't been funded, given what we know already, but I think it would certainly increase confidence. You know, again, it doesn't prove just because it works in dogs doesn't prove it's going to work the same way in people. But I think it would certainly increase confidence that that's more likely to be true because of what I alluded to earlier, that that, you know, dogs check a couple of the big the boxes for the big weaknesses in mice, the genetic piece and the environmental piece. They're just, you know, much, much more similar to humans in being genetically diverse and sharing our environment. So it would certainly, I think, raise confidence that rapamycin is likely to have more likely to have benefits in people maybe than the confidence is right now. So a few takeaways about my son and Matt's trial. So first of all, it's important to emphasize that my son is already in use. So the idea is to repurpose it for aging and for broader consumption. This is why we call it a low hanging fruit. But the other side of it is that it's off patent. So the motivation to fund those trials is pretty low because the payoff isn't great financially. But the good news is that some really talented people are working on it. There are actual human trials taking place right now and I will link to them in the description below. So the bottom line for me is that whether you do optimize your health or not, this whole preoccupation will become naturally obsolete once we have proper medical response Is this Life is just too interesting to be all about life maintenance, and it's certainly not a virtue to direct all of your attention. There. And I do think it depends on the person. But if you feel that this has taken over your life, then I would suggest that you reconsider, because it also it can't be good when it comes to your physical health to be so obsessed with this kind of stuff. So I'm curious to hear what you think and if anything that Matt mentioned is something that you're able and willing to try. I got to say that I feel a bit overwhelmed right now, but looking forward to hearing from you and until next time.